Kirsten Müller-Vahl, Hannover
Literatur
1. Abuzzahab FE Sr, Anderson FO. Gilles de la Tourette’s syndrome; international registry. Minn Med 1973;56:492–6
2. Abi-Jaoude E, Bhikram T, Parveen F, Levenbach J, et al. A double-blind, randomized, controlled crossover trial of Cannabis in adults with Tourette syndrome. Cannabis Cannabinoid Res 2022.
3. Aguirregomozcorta M, Pagonabarraga J, Diaz-Manera J, et al. Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck. Parkinsonism Relat Disord 2008;14:443–5.
4. Akbari M, Jamshidi S, Sheikhi S, Alijani F, et al. Aripiprazole and its adverse effects in the form of impulsive- compulsive behaviors: a systematic review of case reports. Psychopharmacology (Berl) 2024;241:209–23.
5. Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005;65:1941–9.
6. Awaad Y. Tics in Tourette syndrome: new treatment options. J Child Neurol 1999;14:316–9.
7. Balldin J, Berggren U, Eriksson E, Lindstedt G, et al. Guanfacine as an alpha-2-agonist inducer of growth hormone secretion – a comparison with clonidine. Psychoneuroendocrinology 1993;18:45–55.
8. Bastiampillai T, Dhillon R, Mohindra R. Exacerbation of tics secondary to clozapine therapy. Aust N Z J Psychiatry 2008;42:1068–70.
9. Begum M. Clozapine-induced stuttering, facial tics and myoclonic seizures: a case report. Aust N Z J Psychiatry 2005;39:202.
10. Begum G, Nkemjika S, Olayinka O, Olupona T, et al. Clozapine response for vocal tics in Schizophrenic patients: a case report with literature review. Cureus 2021;13:e14111.
11. Ben Djebara M, Worbe Y, Schüpbach M, Hartmann A. Aripiprazole:a treatment for severe coprolalia in „refractory“ Gilles de la Tourette syndrome. Mov Disord 2008;23:438–40.
12. Bodeck S, Lappe C, Evers S. Tic-reducing effects of music in patients with Tourette’s syndrome: Self-reported and objective analysis. J Neurol Sci 2015;352:41–7.
13. Braun A, Mouradian MM, Mohr E, Fabbrini G, et al. Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. J Neurol Neurosurg Psychiatry 1989;52:631–5.
14. Bruggeman R, Linden C van der, Buitelaar JK, Gericke GS, et al. Risperidone versus pimozide in Tourette’s disorder: a comparative double-blind parallelgroup study. J Clin Psychiatry 2001;62:50–6.
15. Brunnauer A, Segmiller FM, Volkamer T, Laux G, et al. Cannabinoids improve driving ability in a Tourette’s patient. Psychiatry Res 2011;190:382.
16. Bruun RD, Budman CL. Risperidone as a treatment for Tourette’s syndrome. J Clin Psychiatry 1996;57:29–31.
17. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;136:317–20.
18. Caprini G, Melotti V. Un grave syndrome ticcosa guarta con haloperidol. Riv Sper Freniat 1961;85:191–6.
19. Cavanna AE, Nani A. Antiepileptic drugs and Tourette syndrome. Int Rev Neurobiol 2013d;112:373–89
20. Coffey B, Jankovic J, Claassen DO, Jimenez-Shahed J, et al. Efficacy and safety of fixed-dose Deutetrabenazine in children and adolescents for Tics associated with Tourette syndrome: a randomized clinical trial. JAMA Netw Open 2021;4:e2129397.
21. Cohen DJ, Young JG, Nathanson JA, Shaywitz BA. Clonidine in Tourette’s syndrome. Lancet 1979;2:551–3.
22. Cohen LS. Quetiapine in treatment-resistant obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2003;42:623–4.
23. Connell PH, Corbett JA, Horne DJ, Mathews AM. Drug treatment of adolescent tiqueurs. A double-blind trial of Diazepam and Haloperidol. Br J Psychiatry 1967;113:375–81.
24. Cui YH, Zheng Y, Yang YP, Liu J, et al. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette’s disorder: a pilot study in China. J Child Adolesc Psychopharmacol 2010;20:291–8.
25. Cummings DD, Singer HS, Krieger M, Miller TL, et al. Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study. Clin Neuropharmacol 2002; 25:325–32.
26. Davis RE, Osorio I. Childhood caffeine tic syndrome. Pediatrics 1998;101:E4.
27. De Jonge JL, Cath DC, Balkom AJ van. Quetiapine in patients with Tourette’s disorder: an open-label, flexible-dose study. J Clin Psychiatry 2007;68:1148–50.
28. Debray P, Messerschmitt P, Lonchamp D, Herbault M. L’utilization du pimozide en pedopsychiatrie. Nouv Presse Med 1972;1:2917–8.
29. Degrauw RS, Li JZ, Gilbert DL. Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome. Pediatr Neurol 2009;41:183–6.
30. Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of Tourette syndrome: a double-blind, placebocontrolled trial. J Clin Psychopharmacol 2002;22:31–9.
31. Du YS, Li HF, Vance A, Zhong YQ, et al. Randomized double-blind multicentre placebocontrolled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry 2008;42:807–13.
32. Eapen V, Katona CLE, Barnes TRE, Robertson MM. Sulpiride-inducedf tardive dyskinesia in a person with Gilles de la Tourette syndrome. J Psychopharmacol 1993a;7:290–2.
33. Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 1988;237:223–9.
34. Farber RH, Angelov A, Kim K, Carmack T, et al. Clinical development of valbenazine for tics associated with Tourette syndrome. Expert Rev Neurother 2021;21:393–404.
35. Farhat LC, Behling E, Landeros-Weisenberger A, et al. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette’s syndrome: a systematic review and network meta-analysis. Lancet Child Adolesc Health 2023;7:112–26.
36. Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 1999;9:115–23.
37. Flockhart DA, Drici MD, Kerbusch T, Soukhova N, Richard E, Pearle PL, Mahal SK, Babb VJ. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000;20:317–24.
38. Fountoulakis KN, Panagiotidis P. Tardive Tourette-like syndrome in a patient treated with paliperidone. J Neuropsychiatry Clin Neurosci 2011;23:E35–6.
39. Fountoulakis KN, Siamouli M, Kantartzis S, Panagiotidis P, et al. Acute dystonia with low-dosage aripiprazole in Tourette’s disorder. Ann Pharmacother 2006;40:775–7.
40. Fulop G, Phillips RA, Shapiro AK, Gomes JA, et al. ECG changes during haloperidol and pimozide treatment of Tourette’s disorder. Am J Psychiatry 1987;144:673–5.
41. Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 2002;41:330–6.
42. Gancher S, Conant-Norville D, Angell R. Treatment of Tourette’s syndrome with transdermal clonidine: a pilot study. J Neuropsychiatry Clin Neurosci 1990;2:66–9.
43. Ganos C, Sarva H, Kurvits L, Gilbert DL, et al. Clinical practice patterns in tic disorders among movement disorder society members.Tremor Other Hyperkinet Mov (NY) 2021;11:43.
44. Garvey MA, Perlmutter SJ, Allen AJ, Hamburger S, et al. A pilot study of penicillin prophylaxis for neuropsychiatric exacerbations triggered by streptococcal infections Biol Psychiatry 1999;45:1564–71.
45. Gerasch S, Kanaan AS, Jakubovski E, Müller-Vahl KR. Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with Gilles de la Tourette syndrome. Front Neurosci 2016;10:416.
46. Ghanizadeh A. Systemic review of aripiprazole for the treatment of children and adolescents with tic disorders. Neurosciences (Riyadh) 2012;17:200–4.
47. Giakas WJ. Risperidone treatment for a Tourette’s disorder patient with comorbid obsessive-compulsive disorder. Am J Psychiatry 1995;152:1097–8.
48. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004;43:206–14.
49. Gilbert DL, Budman CL, Singer HS, Kurlan R, et al. A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome. Clin Neuropharmacol. 2014;37:26–30.
50. Gilbert DL, Dubow JS, Cunniff TM, Wanaski SP, et al. Ecopipam for Tourette syndrome: a randomized trial. Pediatrics 2023;151:e2022059574.
51. Gilbert DL, Dure L, Sethuraman G, Raab D, et al. Tic reduction with pergolide in a randomized controlled trial in children. Neurology 2003;60:606–11.
52. Gilbert DL, Murphy TK, Jankovic J, Budman CL, et al. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: a randomized, placebo-controlled crossover study. Mov Disord 2018;33:1272–80.
53. Gilbert DL, Sethuraman G, Sine L, Peters S, et al. Tourette’s syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology 2000;54:1310–5.
54. Glaze DG, Frost JD Jr, Jankovic J. Sleep in Gilles de la Tourette’s syndrome: disorder of arousal. Neurology 1983;33:586–92.
55. Goetz CG, Stebbins GT, Thelen JA. Talipexole and adult Gilles de la Tourette’s syndrome: double-blind, placebo-controlled clinical trial. Mov Disord 1994;9:315–7.
56. Goetz CG, Tanner CM, Wilson RS, Carroll VS, et al. Clonidine and Gilles de la Tourette’s syndrome: double-blind study using objective rating methods. Ann Neurol1987a;21:307–10.
57. Gordon M, Cologne SE, Hartlein J, Koller J, et al. A pilot study of levopoda for treatment of tics in children and adults [Poster].Washington University 2013. URL: f1000research.com/posters/1093664 (Zugriff am 07.03.2023) ((bitte Link checken!))
58. Guan CH, Tsai SJ. Paliperidone in the treatment of Tourette’s syndrome with comorbid schizophrenia. Psychiatry Clin Neurosci 2013;67:128.
59. Gulisano M, Calì PV, Cavanna AE, Eddy C, et al. Cardio-vascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci 2011;32:1213–7.
60. Guo S, Hu S, Liu H, et al. Efficacy and safety of choudongning capsule in children with Tourette’s syndrome of spleen deficiency and phlegm accumulation in phase II clinic. Zhongcaoyao 2018;49:891–96.
61. Hasan A, Rothenberger A, Münchau A, Wobrock T, et al. Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. J Clin Psychopharmacol 2010;30:190–2.
62. Hedderick EF, Morris CM, Singer HS. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009;40:420–5.
63. Hemming M, Yellowlees PM. Effective treatment of Tourette’s syndrome with marijuana. J Psychopharmacol 1993;7:389–91.
64. Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attentiondeficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 2014;53:153–73.
65. Ho CS, Chen HJ, Chiu NC, Shen EY, Lue HC. Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc 2009;108:788–93.
66. Hoekstra PJ, Minderaa RB, Kallenberg CG. Lack of effect of intravenous immunoglobulins on tics: a double-blind placebocontrolled study. J Clin Psychiatry 2004b;65:537–42.
67. Horrigan JP, Barnhill LJ. Guanfacine and secondary mania in children. J Affect Disord 1999;54:309–14.
68. Hu S, Ma R, Tian T, et al. Phase III clinical study of changma xifeng tablets in the treatment of children with multiple tics. Xiandai Yaowu Yu Linchuang 2014;29:1044–49.
69. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423–9.
70. Jakubovski E, Müller-Vahl K. Speechlessness in Gilles de la Tourette syndrome: cannabis-based medicines improve severe vocal blocking tics in two patients. Int J Mol Sci 2017;18:1739.
71. Jakubovski E, Pisarenko A, Fremer C, Haas M, et al. The CANNA-TICS study protocol: a randomized multi-center double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders. Front Psychiatry 2020;11:575826.
72. Janik P, Szejko N. Aripiprazole in treatment of Gilles de la Tourette syndrome – New therapeutic option. Neurol Neurochir Pol 2018;52:84–87.
73. Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994;9:347–9.
74. Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, et al. Safety and efficacy of flexible-dose Deutetrabenazine in children and adolescents with Tourette syndrome: a randomized clinical trial. JAMA Netw Open. 2021;4:e2128204.
75. Jankovic J, Jimenez-Shahed J, Brown L. A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette Syndrome. J Neurol Neurosurg Psychiatry 2010b;81:70–3.
76. Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor other hyperkinet. Mov (NY). 2016;6:422.
77. Kanaan AS, Jakubovski E, Müller-Vahl K. Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette syndrome following treatment with nabiximols. Brain Sci 2017b;7:47.
78. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22:193–7.
79. Kim BN, Lee CB, Hwang JW, Shin MS, et al. Effectiveness and safety of risperidone for children and adolescents with chronic tic or Tourette disorders in Korea. J Child Adolesc Psychopharmacol 2005;15:318–24.
80. King A, Harris P, Fritzell J, Kurlan R. Syncope in children with Tourette’s syndrome treated with guanfacine. Mov Disord 2006;21:419–20.
81. Kompoliti K, Fan W, Leurgans S. Complementary and alternative medicine use in Gilles de la Tourette syndrome. Mov Disord 2009;24:2015–9.
82. Kurlan R, Crespi G, Coffey B, Mueller-Vahl K, et al. Pramipexole for TS trial investigators. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette’s syndrome. Mov Disord 2012;27:775–8.
83. Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol 2000;57:1190–3.
84. Leckman JF, Detlor J, Harcherik DF, Ort S, et al. Shortand long-term treatment of Tourette’s syndrome with clonidine: a clinical perspective. Neurology 1985;35:343–51.
85. Leckman JF, Hardin MT, Riddle MA, Stevenson J, et al. Clonidine treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1991;48:324–8.
86. Ledbetter M. Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol 2005;15:331–3.
87. Liu Y, Ni H, Wang C, Li L, et al. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette’s disorder: a meta-analysis. J Child Adolesc Psychopharmacol 2016;26:436–41.
88. Lotia M, Jankovic J. Botulinum toxin for the treatment of tremor and tics. Semin Neurol 2016;36:54–63.
89. Ma R, Hu SY, Tian T, Wei XW, e al. Xifeng zhidong tablet and the placebo control treatment of tic disorder children patients of internal disturbance of Gan-wind with phlegm syndrome: a clinical study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014;34(4):426–30. Chinese PMID: 24812897
90. Macerollo A, Martino D, Cavanna AE, Gulisano M, et al. Refractoriness to pharmacological treatment for tics:a multicentre European audit. J Neurol Sci. 2016;366:136–138.
91. Mantel BJ, Meyers A, Tran QY, Rogers S, et al. Nutritional supplements and complementary/alternative medicine in Tourette syndrome. J Child Adolesc Psychopharmacol 2004;14:582–9.
92. Marras C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology 2001;56:605–10.
93. Martínez-Granero MA, García-Pérez A, Montañes F. Levetiracetam as an alternative therapy for Tourette syndrome. Neuropsychiatr Dis Treat 2010;6:309–16.
94. Martino D, Malaty I, Müller-Vahl K, Nosratmirshekarlou E, et al. Movement disorders society Tourette syndrome study group. treatment failure in persistent tic disorders: an expert clinicians’ consensus-based definition. Eur Child Adolesc Psychiatry 2021a
95. Martino D, Schrag A, Anastasiou Z, Apter A, et al. Association of group a streptococcus exposure and exacerbations of chronic tic disorders: a multinational prospective cohort study. Neurology. 2021b;96:e1680-e1693.
96. Masi G, Gagliano A, Siracusano R, Berloffa S, et al. Aripiprazole in children with Tourette’s disorder and co-morbid attention-deficit/hyperactivity disorder: a 12-week, open-label, preliminary study. J Child Adolesc Psychopharmacol 2012;22:120–5.
97. Moretti A. Is botulinum toxin effective and safe for motor and phonic tics in patients affected by Tourette syndrome? A cochrane review summary with commentary. Dev Med Child Neurol 2020;62:274–6.
98. Mosley PE, Webb L, Suraev A, Hingston L, et al. Tetrahydrocannabinol and cannabidiol in Tourette syndrome. NEJM Evid 2023;2(9):EVIDoa2300012.
99. Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol 2003;13:295–9.
100. Müller-Vahl, KR. Tourette-Syndrom und andere Tic-Störungen im Kindes- und Erwachsenenalter. 3. Auflage. Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft, 2024.
101. Müller-Vahl KR. The treatment of Tourette’s syndrome: current opinions. Expert Opin Pharmacother 2002;3:899–914.
102. Müller-Vahl KR, Buddensiek N, Geomelas M, Emrich HM. The influence of different food and drink on tics in Tourette syndrome. Acta Paediatr 2008a;97:442–6.
103. Müller-Vahl KR, Fremer C, Beals C, Ivkovic J,et al. . Endocannabinoid modulation using monoacylglycerol lipase inhibition in Tourette syndrome: A phase 1 randomized, placebo-controlled study. Pharmacopsychiatry 2022c;55:148–56.
104. Müller-Vahl KR, Fremer C, Beals C, Ivkovic J, et al. Monoacylglycerol lipase inhibition in Tourette syndrome: A 12-week, randomized, controlled study. Mov Disord 2021a;36:2413–8.
105. Müller-Vahl KR, Koblenz A, Jöbges M, Kolbe H, et al. Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 2001;34:19–24.
106. Müller-Vahl KR, Kolbe H, Dengler R. Gilles de la Tourette-Syndrom: Einfluß von Nikotin, Alkohol und Marihuana auf die klinische Symptomatik. Nervenarzt 1997b;68:985–9.
107. Müller-Vahl KR, Pisarenko A, Ringlstetter R, Cimpianu CL, et al. The effect of nabiximols on driving ability in adults with chronic tic disorders: results of a substudy analysis of the double-blind, randomized, placebo-controlled CANNA-TICS Trial. Cannabis Cannabinoid Res. 2024.
108. Müller-Vahl KR, Pisarenko A, Szejko N, Haas M, et al. A CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders – Results of a prospective, multicenter, randomized, double-blind, placebo-controlled, phase IIIb superiority study. Psychiatry Res 2023b;323:115135.
109. Müller-Vahl KR, Prevedel H, Theloe K, Kolbe H, et al. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 2003b;28:384–8.
110. Müller-Vahl KR, Schneider U, Emrich HM. Combined treatment of Tourette syndrome with 69-THC and dopamine receptor antagonists. J Cannabis Therap 2002b;2:145–154.
111. Müller-Vahl KR, Schneider U, Koblenz A, Jöbges M, et al. Treatment of Tourette’s syndrome with delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002c;35:57–61.
112. Müller-Vahl KR, Schneider U, Kolbe H, Emrich HM. Treatment of Tourette syndrome with delta-9-Tetrahydrocannabinol. Am J Psychiatry 1999;156:495.
113. Müller-Vahl KR, Schneider U, Prevedel H, Theloe K, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003c;64:459–65.
114. Müller-Vahl KR, Szejko N, Verdellen C, Roessner V, et al. European clinical guidelines for Tourette syndrome and other tic disorders: summary statement. Eur Child Adolesc Psychiatry 2022b;31:377–382.
115. Murphy ML, Pichichero ME. Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group a streptococcal infection (PANDAS). Arch Pediatr Adolesc Med 2002;156:356–61.
116. Murphy TK, Fernandez TV, Coffey BJ, Rahman O, et al. Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. J Child Adolesc Psychopharmacol 2017;27:762–70.
117. Onofrj M, Paci C, D’Andreamatteo G, Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind crossover study vs. low-dose pimozide. J Neurol 2000;247:443–6.
118. Orth M, Amann B, Robertson MM, Rothwell JC. Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine. Brain 2005a;128:1292–300.
119. Pappadopulos E, Woolston S, Chait A, Perkins M, et al. Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry 2006;15:27–39.
120. Párraga HC, Párraga KL, Harris DK, Campbell TS. Abdominal tics during atomoxetine treatment in a child with ADHD: evaluation and differential diagnosis. CNS Spectr 2008;13:E1.
121. Párraga HC, Parraga MI, Harris DK. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention deficit hyperactivity disorder. Int J Psychiatry Med 2007; 37:415–24.
122. Patel H, Nguyen K, Lehman E, Mainali G, et al. A use of complementary and alternative medicine in children with Tourette syndrome. J Child Neurol. 2020;35(8):512–6.
123. Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999;354:1153–8.
124. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129–80.
125. Pichler EM, Kawohl W, Seifritz E, Roser P. Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: a case report. Int J Psychiatry Med. 2019;54:150–56.
126. Porta M, Maggioni G, Ottaviani F, Schindler A. Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A. Neurol Sci 2004;24:420–3.
127. Porta M, Sassi M, Ali F, Cavanna AE, et al. Neurosurgical treatment for Gilles de la Tourette syndrome: the Italian perspective. J Psychosom Res 2009b;67:585–90.
128. Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, et al. Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019a;92:907–15. (Erratum in: Neurology 2019;93:415.)
129. Pringsheim T, Okun MS, Müller-Vahl K, Martino D, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019b;92:896–906.
130. Rath JJ, Tavy DL, Wertenbroek AA, Woerkom TC van, et al. Botulinum toxin type A in simple motor tics: short-term and long-term treatment-effects. Parkinsonism Relat Disord 2010;16:478–81.
131. Regeur L, Pakkenberg B, Fog R, Pakkenberg H. Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette’s syndrome. J Neurol Neurosurg Psychiatry 1986;49:791–5.
132. Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain 2000;123:425–62.
133. Robertson MM, Gourdie A. Familial Tourette’s syndrome in a large British pedigree. Associated psychopathology, severity, and potential for linkage analysis. Br J Psychiatry 1990;156:515–21.
134. Roessner V, Eichele H, Stern JS, Skov L, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry 2022;31:425–41.
135. Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, et al. ESSTS Guidelines Group. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 2011b;20:173–96.
136. Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette’s syndrome. Am J Psychiatry 1978;135:585–7.
127. Sallee F, Kohegyi E, Zhao J, McQuade R, et al. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol 2017;27:771–81.
138. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, DittmanVM, Chappell PB. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39:292–9.
139. Sallee FR, Miceli JJ, Tensfeldt T, Robarge L, et al. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45:720–8.
140. Sallee FR, Nesbitt L, Jackson C, Sine L,et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette’s disorder. Am J Psychiatry 1997;154:1057–62.
141. Salloway S, Stewart CF, Israeli L, Morales X, Rasmussen S, Blitzer A, Brin MF. Botulinum toxin for refractory vocal tics. Mov Disord 1996; 11:746–8.
142. Salvador A, Worbe Y, Delorme C, Coricelli G, ewt al. Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome. Sci Rep. 2017;7:6292.
143. Sandor P, Musisi S, Moldofsky H, Lang A. Tourette syndrome: a follow-up study. J Clin Psychopharmacol 1990;10:197–9.
144. Sandor P, Stephens RJ. Risperidone treatment of aggressive behavior in children with Tourette syndrome. J Clin Psychopharmacol 2000;20:710–2.
145. Sandyk R, Awerbuch G. Marijuana and Tourette’s Syndrome. J Clin Psychopharmacol 1988;8:444–5.
146. Saxena S, Wang D, Bystritsky A, Baxter LR Jr: Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303–6.
147. Scahill L, Chappell PB, Kim YS, Schultz RT, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158:1067–74.
148. Scahill L, Leckman JF, Schultz RT, Katsovich L, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003;60:1130–5.
149. Schrag AE, Martino D, Wang H, Ambler G, et al. Lack of association of group A streptococcal infections and onset of tics: European multicenter tics in children study. Neurology 2022;98:e1175-e1183.
150. Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome. Mov Disord 1996;11:431–3.
151. Sears J, Patel NC. Development of tics in a thirteen-yearold male following atomoxetine use. CNS Spectr 2008;13:301–3.
152. Seignot MJN. Un cas de maladie des tics de Gilles de la Tourette gueri par le R-1625. Ann Med Psychiatry 1961;119:578–9.7
153. Shapiro AK, Shapiro E. Clonidine and haloperidol in Gilles de la Tourette syndrome. Arch Gen Psychiatry 1981;38:1183–5.
154. Shapiro AK, Shapiro E. Controlled study of pimozide vs. Placebo in Tourette’s syndrome. J Am Acad Child Psychiatry 1984;23:161–73.
155. Shapiro AK, Shapiro E, Bruun RD, Sweet RD. Gilles de la Tourette Syndrome. New York:Raven Press, 1978.
156. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette syndrome with pimozide. Am J Psychiatry 1983a;140:1183–6.
157. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette’s syndrome with clonidine and neuroleptics. Arch Gen Psychiatry 1983b;40:1235–40.
158. Shapiro AK, Shapiro E, Wayne H. Treatment of Tourette’s syndrome with haloperidol, review of 34 cases. Arch Gen Psychiatry 1973;28:92–7.
159. Shapiro E, Shapiro AK, Fulop G, Hubbard M, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1989;46:722–30.
160. Silver AA, Shytle RD, Philipp MK, Wilkinson BJ, et al. Transdermal nicotine and haloperidol in Tourette’s disorder: a double-blind placebo-controlled study. J. Clin. Psychiatry 2001a; 62:707–14.
161. Singer HS, Brown J, Quaskey S, Rosenberg LA, The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995;95:74–81.
162. Singer HS, Gammon K, Quaskey S. Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1985–86;12:71–4.
163. Song PP, Jiang L, Li XJ, Hong SQ, et al. The efficacy and tolerability of the clonidine transdermal patch in the treatment for children with tic disorders: A prospective, open, single-group, self-controlled study. Front Neurol 2017;8:32.
164. Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 2008;11:470–81.
165. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessivecompulsive and related disorders. J Clin Psychiatry 1997;58:119–22.
166. Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette’s syndrome – a pilot study. J Child Adolesc Psychopharmacol 2004;14:255–66.
167. Szejko N, Jakubovski E, Fremer C, Kunert K, et al. Delta-9-tetrahydrocannabinol for the treatment of a child with Tourette syndrome – case report. EJMCR 2018;2:39–41.
168. Szejko N, Jakubovski E, Fremer C, Müller-Vahl KR. Vaporized cannabis is effective and well-tolerated in an adolescent with Tourette syndrome. Med Cannabis Cannabinoids 2019;2:60–63.
169. Szejko N, Saramak K, Lombroso A, Müller-Vahl K. Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome. Neurol Neurochir Pol. 2022;56:28–38.
170. Szejko N, Worbe Y, Hartmann A, Visser-Vandewalle V, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part IV: deep brain stimulation. Eur Child Adolesc Psychiatry 2022b;31:443–461.
171. The Tourette Syndrome Study Group. Short-term versus longer term pimozide therapy in Tourette’s syndrome: a preliminary study. Neurology 1999;52:874–7.
172. Thomas N, Swamidhas P, Russell S, Angothu H. Tardive dyskinesia following risperidone treatment in Tourette’s syndrome. Neurol India 2009;57:94–5.
173. Tirodkar M. Tourette syndrome in Indian Ayurvedic medical practice. J Dev Behav Pediatr. 2010;31:173–4.
173a Toru M, Moriya H, Yamamoto K, Shimazono Y. A double-blind comparison of sulpiride with chlordiazepoxide in neurosis. Folia Psychiatr Neurol Jpn 1976;30:153–64.
174. Trainor D, Evans L, Bird R. Severe motor and vocal tics controlled with Sativex®. Australas Psychiatry 2016;24:541–4.
175. Trillet M, Moreau T, Daléry J, de Villard R, et al. Treatment of Gilles de la Tourette’s disease with amisulpride. Presse Med 1990;19:175.
176. Trimble MR, Whurr R, Brookes G, Robertson MM. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 1998;13:617–9.
177. Vincent DA Jr. Botulinum toxin in the management of laryngeal tics. J Voice 2008;22:251–6.
178. Waldon K, Hill J, Termine C, Balottin U, et al. Trials of pharmacological interventions for Tourette syndrome: a systematic review. Behav Neurol. 2013;26:265–73.
179. Wang LJ, Chou WJ, Chou MC, Gau SS. The effectiveness of aripiprazole for tics, social adjustment, and parental stress in children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol. 2016 Jun;26(5):442–8.
180. Wang S, Xiong Z, Cui Y, Fan F, et al. Placebo and nocebo responses in pharmacological trials of tic disorders: a meta-analysis. Mov Disord. 2024 Jan 21.
181. Weisman H, Qureshi IA, Leckman JF, Scahill L, et al. Systematic review: pharmacological treatment of tic disorders–efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev 2013;37:1162–71.
182. Wenzel C, Kleimann A, Bokemeyer S, Müller-Vahl KR. Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. J Clin Psychopharmacol. 2012;32:548–50.
183. Whittington C, Pennant M, Kendall T, Glazebrook C, et al. Practitioner review: Treatments for Tourette syndrome in children and young people – a systematic review. J Child Psychol Psychiatry 2016;57:988–1004.
184. Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord 2014;29:126–30.
185. Winter C, Heinz A, Kupsch A, Ströhle A. Aripiprazole in a case presenting with tourette syndrome and obsessive-compulsive disorder. J Clin Psychopharmacol 2008;28:452–4.
186. Yamamuro K, Makinodan M, Ota T, Iida J, et al. Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette’s disorder. Ann Gen Psychiatry 2014;13:13.
187. Yang C, Hao Z, Zhang LL, Zhu CR, et al. Comparative efficacy and safety of antipsychotic drugs for tic disorders: A systematic review and bayesian network meta-analysis. Pharmacopsychiatry. 2019;52:7–15.
188. Yang CS, Zhang LL, Zeng LN, Huang L, et al. Topiramate for Tourette’s syndrome in children: a meta-analysis. Pediatr Neurol 2013;49:344–50.
189. Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry 2013;74:e772–80.
190. Yu L, Yan J, Wen F, Wang F, et al. Revisiting the efficacy and tolerability of topiramate for tic disorders: a meta-analysis. J Child Adolesc Psychopharmacol 2020b;30:316–25.
191. Zhao L, Li AY, Lv H, Liu FY, et al. Traditional chinese medicine ningdong granule: the beneficial effects in Tourette’s 307 disorder. J Int Med Res 2010;38:169–75
192. Zheng W, Li XB, Xiang YQ, Zhong BL, et al. Aripiprazole for Tourette’s syndrome: a systematic review and meta-analysis. Hum Psychopharmacol 2016a;31:11–8.
193. Zheng Y, Zhang ZJ, Han XM, Ding Y, et al. A proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial. J Child Psychol Psychiatry. 2016b;57:74–83.
*Modifizierter, gekürzter Nachdruck von Kapitel 15, „Behandlung von Tics: Pharmakotherapie“, aus: Müller-Vahl, KR. Tourette-Syndrom und andere Tic-Störungen im Kindes- und Erwachsenenalter. 3. Auflage. Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft, 2024.
Prof. Dr. Kirsten R. Müller-Vahl, Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Zentrum für Seelische Gesundheit, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, E-Mail: mueller-vahl.kirsten@mh-hannover.de
Psychopharmakotherapie 2024; 31(05):197-200